Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients

References

• AkbarS, AlorainyMS. The current status of beta blockers’ use in the management of hypertension. Saudi Med J. 2014;35(11):1307–1317.25399206
   PubMed Web of Science ®Google Scholar
• KalamMN, RasoolMF, RehmanAU, AhmedN. Clinical pharmacokinetics of propranolol hydrochloride: a review. Curr Drug Metab. 2020;21(2):89–105. doi:10.2174/138920022166620041409464432286940
   PubMed Web of Science ®Google Scholar
• de FranchisR. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53(4):762–768. doi:10.1016/j.jhep.2010.06.00420638742
   PubMed Web of Science ®Google Scholar
• LebrecD, PoynardT, HillonP, BenhamouJ-P. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med. 1981;305(23):1371–1374. doi:10.1056/NEJM1981120330523027029276
   PubMed Web of Science ®Google Scholar
• XuX, GuoX, De StefanoV, et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int. 2019:1–14. doi:10.1007/s12072-018-09923-2
   Web of Science ®Google Scholar
• NiesAS, ShandDG. Clinical pharmacology of propranolol. Circulation. 1975;52(1):6–15. doi:10.1161/01.CIR.52.1.61093761
   PubMed Web of Science ®Google Scholar
• StenT, QvisenS, UutelaP, LuukkanenL, KostiainenR, FinelM. Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10. Drug Metab Dispos. 2006;34(9):1488–1494. doi:10.1124/dmd.106.01037116763014
   PubMed Web of Science ®Google Scholar
• PatersonJ, ConollyM, DolleryC, HayesA, CooperR. The pharmacodynamics and metabolism of propranolol in man. Pharmacologia Clinica. 1970;2(3):127–133. doi:10.1007/BF00420338
   Google Scholar
• KornhauserD, WoodA, VestalR, WilkinsonG, BranchR, ShandD. Biological determinants of propranolol disposition in man. Clin Pharmacol Ther. 1978;23(2):165–174. doi:10.1002/cpt1978232165620476
   PubMed Web of Science ®Google Scholar
• AvramMJ, KrejcieTC, HenthornTK, NiemannCU. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution. J Pharmacol Exp Ther. 2004;311(2):617–624. doi:10.1124/jpet.104.07009415197245
   PubMed Web of Science ®Google Scholar
• RasoolMF, KhalilF, LaerS. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. Clin Pharmacokinet. 2015;54(9):943–962. doi:10.1007/s40262-015-0253-725773479
   PubMed Web of Science ®Google Scholar
• RasoolMF, KhalidR, ImranI, et al. Investigating the role of altered systemic albumin concentration on the disposition of theophylline in adult and pediatric patients with asthma by using the physiologically based pharmacokinetic approach. Drug Metab Dispos. 2020;48(7):570–579. doi:10.1124/dmd.120.09096932393652
   PubMed Web of Science ®Google Scholar
• KovarL, SchräpelC, SelzerD, et al. Physiologically-based pharmacokinetic (PBPK) modeling of buprenorphine in adults, children and preterm neonates. Pharmaceutics. 2020;12(6):578. doi:10.3390/pharmaceutics12060578
   Web of Science ®Google Scholar
• RasoolMF, KhalidS, MajeedA. Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting rifampicin exposure in tuberculosis and cirrhosis populations. Pharmaceutics. 2019;11(11):578. doi:10.3390/pharmaceutics11110578
   Web of Science ®Google Scholar
• CuiC, Sia Jie EnV, TuS, et al. Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects. Br J Clin Pharmacol. 2020. doi:10.1111/bcp.14609
   Web of Science ®Google Scholar
• SrinivasanA. Propranolol: a 50-year historical perspective. Ann Indian Acad Neurol. 2019;22(1):21. doi:10.4103/aian.AIAN_201_1830692755
   PubMed Web of Science ®Google Scholar
• KhalilF, LaerS. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. AAPS J. 2014;16(2):226–239. doi:10.1208/s12248-013-9555-624399240
   PubMed Web of Science ®Google Scholar
• JohnsonTN, BousseryK, Rowland-YeoK, TuckerGT, Rostami-HodjeganA. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189–206. doi:10.2165/11318160-000000000-0000020170207
   PubMed Web of Science ®Google Scholar
• EdgintonAN, WillmannS. Physiology-based simulations of a pathological condition. Clin Pharmacokinet. 2008;47(11):743–752. doi:10.2165/00003088-200847110-0000518840029
   PubMed Web of Science ®Google Scholar
• LevittDG. PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol. 2002;2:5. doi:10.1186/1472-6904-2-512182760
   PubMedGoogle Scholar
• KiriyamaA, HonboA, IgaK. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans. Int J Pharm. 2008;349(1–2):53–60. doi:10.1016/j.ijpharm.2007.07.01917765415
   PubMed Web of Science ®Google Scholar
• RoseRH, TurnerDB, NeuhoffS, JameiM. Incorporation of the time-varying postprandial increase in splanchnic blood flow into a PBPK model to predict the effect of food on the pharmacokinetics of orally administered high-extraction drugs. Aaps j. 2017;19(4):1205–1217. doi:10.1208/s12248-017-0099-z28526963
   PubMed Web of Science ®Google Scholar
• ZhangM, YouX, KeM, et al. Prediction of ticagrelor and its active metabolite in liver cirrhosis populations using a physiologically based pharmacokinetic model involving pharmacodynamics. J Pharm Sci. 2019;108(8):2781–2790. doi:10.1016/j.xphs.2019.03.02830928308
   PubMed Web of Science ®Google Scholar
• RasoolMF, KhalilF, LäerS. Optimizing the clinical use of carvedilol in liver cirrhosis using a physiologically based pharmacokinetic modeling approach. Eur J Drug Metab Pharmacokinet. 2017;42(3):383–396. doi:10.1007/s13318-016-0353-227313074
   PubMed Web of Science ®Google Scholar
• LiR, BartonHA, MaurerTS. A mechanistic pharmacokinetic model for liver transporter substrates under liver cirrhosis conditions. CPT Pharmacometrics Syst Pharmacol. 2015;4(6):338–349.26225262
   PubMedGoogle Scholar
• CidE, MellaF, LucchiniL, CarcamoM, MonasterioJ. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. Biopharm Drug Dispos. 1986;7(6):559–566. doi:10.1002/bdd.25100706053828485
   PubMed Web of Science ®Google Scholar
• WilsonTW, FirorWB, JohnsonGE, et al. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. Clin Pharmacol Ther. 1982;32(6):676–685. doi:10.1038/clpt.1982.2237140133
   PubMed Web of Science ®Google Scholar
• RegardhCG, JohnssonG, JordoL, LungborgP, PerssonBA, RonnO. Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. J Cardiovasc Pharmacol. 1980;2(6):715–723. doi:10.1097/00005344-198011000-000026160322
   PubMed Web of Science ®Google Scholar
• MouldGP, CloughJ, MorrisBA, StoutG, MarksV. A propranolol radioimmunoassay and its use in the study of its pharmacokinetics following low doses. Biopharm Drug Dispos. 1981;2(1):49–57. doi:10.1002/bdd.25100201067236871
   PubMed Web of Science ®Google Scholar
• GreenblattDJ, ScavoneJM, HarmatzJS, EngelhardtN, ShaderRI. Cognitive effects of beta-adrenergic antagonists after single doses: pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo. Clin Pharmacol Ther. 1993;53(5):577–584. doi:10.1038/clpt.1993.738098277
   PubMed Web of Science ®Google Scholar
• RoscoeR, CooperJ, WilsonTW, JoshiNN, MidhaKK. The relative bioavailability of a commercial propranolol hydrochloride tablet in man. Biopharm Drug Dispos. 1982;3(2):105–114. doi:10.1002/bdd.25100302047104460
   PubMed Web of Science ®Google Scholar
• GiudicelliJF, RicherC, ChauvinM, IdrissiN, BerdeauxA. Comparative beta-adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man. Br J Clin Pharmacol. 1977;4(2):135–140. doi:10.1111/j.1365-2125.1977.tb00684.x16632
   PubMed Web of Science ®Google Scholar
• HuangSM, WeintraubHS, MarriottTB, MarinanB, AbelsR. Etintidine-propranolol interaction study in humans. J Pharmacokinet Biopharm. 1987;15(6):557–568. doi:10.1007/BF010684122897462
   PubMedGoogle Scholar
• AngermayrB, CejnaM, KarnelF, et al. Child-pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52(6):879–885. doi:10.1136/gut.52.6.87912740346
   PubMed Web of Science ®Google Scholar
• PessayreD, LebrecD, DescatoireV, PeignouxM, BenhamouJP. Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology. 1978;74(3):566–571. doi:10.1016/0016-5085(78)90297-4631487
   PubMed Web of Science ®Google Scholar
• KostewiczES, AaronsL, BergstrandM, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:300–321.24060672
   PubMed Web of Science ®Google Scholar
• SchlenderJ-F, TeutonicoD, CoboekenK, et al. A physiologically-based pharmacokinetic model to describe ciprofloxacin pharmacokinetics over the entire span of life. Clin Pharmacokinet. 2018;57(12):1613–1634. doi:10.1007/s40262-018-0661-629737457
   PubMed Web of Science ®Google Scholar
• VogelpoelH, WelinkJ, AmidonG, et al. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci. 2004;93(8):1945–1956. doi:10.1002/jps.2013115236445
   PubMed Web of Science ®Google Scholar
• TakamatsuN, WelageLS, IdkaidekNM, et al. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res. 1997;14(9):1127–1132. doi:10.1023/A:10121342190959327437
   PubMed Web of Science ®Google Scholar
• WilkinsonGR, ShandDG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377–390. doi:10.1002/cpt19751843771164821
   PubMed Web of Science ®Google Scholar
• EmotoC, MuraseS, IwasakiK. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica. 2006;36(8):671–683. doi:10.1080/0049825060070977816891248
   PubMed Web of Science ®Google Scholar
• ZhangY, HuoM, ZhouJ, XieS. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput Methods Programs Biomed. 2010;99(3):306–314. doi:10.1016/j.cmpb.2010.01.00720176408
   PubMed Web of Science ®Google Scholar
• T’jollynH, VermeulenA, Van BocxlaerJ. Pbpk and its virtual populations: the impact of physiology on pediatric pharmacokinetic predictions of tramadol. AAPS J. 2019;21(1):8. doi:10.1208/s12248-018-0277-7
   Web of Science ®Google Scholar
• PierrillasPB, HeninE, BallK, et al. Prediction of human nonlinear pharmacokinetics of a new Bcl-2 inhibitor using PBPK modeling and interspecies extrapolation strategy. Drug Metab Dispos. 2019;47(6):648–656. doi:10.1124/dmd.118.08560530940629
   PubMed Web of Science ®Google Scholar
• MinamiH, KawadaK, SasakiY, et al. Pharmacokinetics and pharmacodynamics of protein‐unbound docetaxel in cancer patients. Cancer Sci. 2006;97(3):235–241. doi:10.1111/j.1349-7006.2006.00166.x16542221
   PubMed Web of Science ®Google Scholar
• TaegtmeyerAB, HaschkeM, TchambazL, et al. A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. PLoS One. 2014;9(6):e97885. doi:10.1371/journal.pone.009788524906133
   PubMed Web of Science ®Google Scholar
• SandleGI, WardA, RawlinsMD, RecordCO. Propranolol absorption in untreated coeliac disease. Clin Sci. 1982;63(1):81–85. doi:10.1042/cs0630081
   PubMed Web of Science ®Google Scholar
• LevineMA, OgilvieRI, LeenenFH. Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. Clin Pharmacol Ther. 1988;43(1):39–48. doi:10.1038/clpt.1988.92826066
   PubMed Web of Science ®Google Scholar
• WilliamsFM, LeeserJE, RawlinsMD. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers. Br J Clin Pharmacol. 1986;22(3):301–308. doi:10.1111/j.1365-2125.1986.tb02891.x3768242
   PubMed Web of Science ®Google Scholar
• Shaw-StiffelTA, WalkerSE, OgilvieRI, LeenenFH. Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol. Clin Pharmacol Ther. 1994;55(6):661–669. doi:10.1038/clpt.1994.838004882
   PubMed Web of Science ®Google Scholar
• SchoorsDF, VercruysseI, MuschG, MassartDL, DupontAG. Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers. Br J Clin Pharmacol. 1990;29(5):497–501. doi:10.1111/j.1365-2125.1990.tb03671.x2350528
   PubMed Web of Science ®Google Scholar
• SalazarDE, MarathePH, FulmorIE, LeeJS, RaymondRH, UdermanHD. Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men. J Clin Pharmacol. 1995;35(11):1109–1118. doi:10.1002/j.1552-4604.1995.tb04035.x8626885
   PubMed Web of Science ®Google Scholar
• SchuppanD, AfdhalNH. Liver cirrhosis. Lancet. 2008;371(9615):838–851. doi:10.1016/S0140-6736(08)60383-918328931
   PubMed Web of Science ®Google Scholar
• ZhaoP. Report from the EMA workshop on qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):71–72.28035755
   PubMedGoogle Scholar
• WagnerC, ZhaoP, PanY, et al. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK. CPT Pharmacometrics Syst Pharmacol. 2015;4(4):226–230.26225246
   PubMedGoogle Scholar
• RoutledgeP. The plasma protein binding of basic drugs. Br J Clin Pharmacol. 1986;22(5):499–506. doi:10.1111/j.1365-2125.1986.tb02927.x3790398
   PubMed Web of Science ®Google Scholar
• PiafskyKM. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet. 1980;5(3):246–262. doi:10.2165/00003088-198005030-000046156048
   PubMed Web of Science ®Google Scholar
• ArthurM, TannerA, PatelC, WrightR, RenwickA, GeorgeC. Pharmacology of propranolol in patients with cirrhosis and portal hypertension. Gut. 1985;26(1):14–19. doi:10.1136/gut.26.1.143965362
   PubMed Web of Science ®Google Scholar
• SharmaS, AgarwalS, GunjanD, et al. Long-term outcomes with carvedilol versus propranolol in patients with index variceal bleed: 6-year follow-up study. J Clin Exp Hepatol. 2020. doi:10.1016/j.jceh.2020.08.009
   Web of Science ®Google Scholar
• MohammedBS, AidooM. Drug treatment of patients with liver cirrhosis in a tertiary hospital in Northern Ghana: does it comply with recommended guidelines? Int J Hepatol. 2020;2020:1–7. doi:10.1155/2020/9750194
   Web of Science ®Google Scholar
• PascalJ-P, CalesP; Group* AMS. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med. 1987;317(14):856–861. doi:10.1056/NEJM1987100131714033306385
   PubMed Web of Science ®Google Scholar
• CalesP, GrassetD, RavaudA, et al. Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol. 1989;27(6):763–770. doi:10.1111/j.1365-2125.1989.tb03438.x2569324
   PubMed Web of Science ®Google Scholar
• WatsonRG, BastainW, LarkinKA, HayesJR, McAinshJA, ShanksRG. A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. Br J Clin Pharmacol. 1987;24(4):527–535. doi:10.1111/j.1365-2125.1987.tb03207.x3689632
   PubMed Web of Science ®Google Scholar
• KuepferL, NiederaltC, WendlT, et al. Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT Pharmacometrics Syst Pharmacol. 2016;5(10):516–531.27653238
   PubMedGoogle Scholar
• FaganTC, WalleT, WalleUK, ConradiEC, HarmonG, GaffneyTE. Early kinetics of intravenous propranolol. Br J Clin Pharmacol. 1982;13(4):571–574. doi:10.1111/j.1365-2125.1982.tb01424.x7066173
   PubMed Web of Science ®Google Scholar
• OlanoffLS, WalleT, CowartTD, WalleUK, OexmannMJ, ConradiEC. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther. 1986;40(4):408–414. doi:10.1038/clpt.1986.1983757404
   PubMed Web of Science ®Google Scholar
• McAinshJ, BaberN, SmithR. Pharmacokinetic and pharmacodynamic studies with long‐acting propranolol. Br J Clin Pharmacol. 1978;6(2):115–121. doi:10.1111/j.1365-2125.1978.tb00835.x678387
   PubMed Web of Science ®Google Scholar
• ZakyS, FouadEA, KotbHI. The effect of rectal ozone on the portal vein oxygenation and pharmacokinetics of propranolol in liver cirrhosis (a preliminary human study). Br J Clin Pharmacol. 2011;71(3):411–415. doi:10.1111/j.1365-2125.2010.03851.x21284700
   PubMed Web of Science ®Google Scholar
• McFarlandJW, AvdeefA, BergerCM, RaevskyOA. Estimating the water solubilities of crystalline compounds from their chemical structures alone. J Chem Inf Comput Sci. 2001;41(5):1355–1359. doi:10.1021/ci010282211604037
   PubMedGoogle Scholar
• PoulinP, TheilFP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–156. doi:10.1002/jps.1000511782904
   PubMed Web of Science ®Google Scholar
• KokateA, LiX, JastiB. Effect of drug lipophilicity and ionization on permeability across the buccal mucosa: a technical note. AAPS PharmSciTech. 2008;9(2):501–504. doi:10.1208/s12249-008-9071-718431653
   PubMed Web of Science ®Google Scholar
• TaylorE, TurnerP. The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma. Br J Clin Pharmacol. 1981;12(4):543–548. doi:10.1111/j.1365-2125.1981.tb01263.x7295488
   PubMed Web of Science ®Google Scholar
• ChoiG-W, LeeY-B, ChoH-Y. Interpretation of non-clinical data for prediction of human pharmacokinetic parameters: in vitro-in vivo extrapolation and allometric scaling. Pharmaceutics. 2019;11(4):168. doi:10.3390/pharmaceutics11040168
   Web of Science ®Google Scholar
• McAinshJ, BaberNS, HolmesBF, YoungJ, EllisSH. Bioavailability of sustained release propranolol formulations. Biopharm Drug Dispos. 1981;2(1):39–48. doi:10.1002/bdd.25100201057236870
   PubMed Web of Science ®Google Scholar